Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)

NCT03998254 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

6000

Enrollment

INDUSTRY

Sponsor class

Conditions

Papillomavirus Infections

Interventions

DRUG: V503
DRUG: Gardasil

Sponsor

Merck Sharp & Dohme LLC